GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has accepted subscriptions for five-year 15% redeemable convertible secured debentures (each, a "Debenture") in the aggregate principal amount of $718,782.85. The issuance of these Debentures represents the second tranche of a private placement offering of the Debentures that was announced on December 31, 2008 whereby the Company's Board of Directors authorized the sale of up to an aggregate principal amount of $3,450,000 of Debentures.
